Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 80

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Major depression

Not recruiting

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lavender Oil
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study of inhaled BX004 bacteriophage treatment for adults with cystic fibrosis who have chronic Pseudomonas aeruginosa lung infection

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IHMA-2121771-1
  • Sponsor:Biomx Ltd.

Hypertension

Not recruiting

Study of orforglipron in people with high blood pressure who are overweight or have obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:S095035
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.